SBI Securities Co. Ltd. acquired a new position in shares of Royalty Pharma plc (NASDAQ:RPRX - Free Report) in the fourth quarter, according to the company in its most recent disclosure with the SEC. The firm acquired 53,542 shares of the biopharmaceutical company's stock, valued at approximately $1,366,000.
Several other institutional investors have also recently added to or reduced their stakes in RPRX. Swedbank AB raised its holdings in shares of Royalty Pharma by 10.3% in the fourth quarter. Swedbank AB now owns 12,164,170 shares of the biopharmaceutical company's stock valued at $310,308,000 after buying an additional 1,136,800 shares during the last quarter. Charles Schwab Investment Management Inc. increased its position in Royalty Pharma by 58.1% during the third quarter. Charles Schwab Investment Management Inc. now owns 3,001,603 shares of the biopharmaceutical company's stock worth $84,915,000 after buying an additional 1,103,341 shares in the last quarter. Two Sigma Advisers LP raised its holdings in shares of Royalty Pharma by 44.7% in the third quarter. Two Sigma Advisers LP now owns 3,033,200 shares of the biopharmaceutical company's stock worth $85,809,000 after acquiring an additional 936,900 shares during the last quarter. Point72 Asset Management L.P. purchased a new stake in shares of Royalty Pharma in the third quarter valued at $14,898,000. Finally, Geode Capital Management LLC boosted its stake in shares of Royalty Pharma by 6.1% during the third quarter. Geode Capital Management LLC now owns 7,265,786 shares of the biopharmaceutical company's stock valued at $205,562,000 after acquiring an additional 417,490 shares during the last quarter. Institutional investors and hedge funds own 54.35% of the company's stock.
Royalty Pharma Trading Down 1.6 %
NASDAQ:RPRX traded down $0.53 during mid-day trading on Thursday, reaching $33.25. The company's stock had a trading volume of 980,908 shares, compared to its average volume of 4,418,182. The company has a debt-to-equity ratio of 0.64, a current ratio of 1.44 and a quick ratio of 1.44. The stock has a market cap of $19.16 billion, a P/E ratio of 22.92, a P/E/G ratio of 2.31 and a beta of 0.47. The company's fifty day simple moving average is $30.57 and its two-hundred day simple moving average is $28.32. Royalty Pharma plc has a twelve month low of $24.05 and a twelve month high of $34.20.
Royalty Pharma (NASDAQ:RPRX - Get Free Report) last released its earnings results on Tuesday, February 11th. The biopharmaceutical company reported $1.15 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.99 by $0.16. Royalty Pharma had a net margin of 37.94% and a return on equity of 24.40%. On average, equities analysts predict that Royalty Pharma plc will post 4.49 EPS for the current year.
Royalty Pharma Increases Dividend
The business also recently declared a quarterly dividend, which will be paid on Monday, March 10th. Shareholders of record on Friday, February 21st will be given a dividend of $0.22 per share. This represents a $0.88 dividend on an annualized basis and a dividend yield of 2.65%. This is an increase from Royalty Pharma's previous quarterly dividend of $0.21. The ex-dividend date is Friday, February 21st. Royalty Pharma's payout ratio is 60.69%.
Analyst Ratings Changes
Separately, TD Cowen upgraded shares of Royalty Pharma to a "strong-buy" rating in a report on Tuesday, December 24th. One research analyst has rated the stock with a hold rating, five have issued a buy rating and one has issued a strong buy rating to the company's stock. Based on data from MarketBeat, the company currently has an average rating of "Buy" and an average price target of $41.60.
Read Our Latest Stock Analysis on Royalty Pharma
Royalty Pharma Company Profile
(
Free Report)
Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovations in the biopharmaceutical industry in the United States. It is also involved in the identification, evaluation, and acquisition of royalties on various biopharmaceutical therapies. In addition, the company collaborates with innovators from academic institutions, research hospitals and not-for-profits, small and mid-cap biotechnology companies, and pharmaceutical companies.
Featured Articles
Before you consider Royalty Pharma, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Royalty Pharma wasn't on the list.
While Royalty Pharma currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
